ATE524446T1 - Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität - Google Patents

Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität

Info

Publication number
ATE524446T1
ATE524446T1 AT07857748T AT07857748T ATE524446T1 AT E524446 T1 ATE524446 T1 AT E524446T1 AT 07857748 T AT07857748 T AT 07857748T AT 07857748 T AT07857748 T AT 07857748T AT E524446 T1 ATE524446 T1 AT E524446T1
Authority
AT
Austria
Prior art keywords
sulfated
serotonin receptor
receptor affinity
mixed serotonin
benzimidazolone derivatives
Prior art date
Application number
AT07857748T
Other languages
English (en)
Inventor
Astrid Volz
Ralf Lotz
Paleari Fabio
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE524446T1 publication Critical patent/ATE524446T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07857748T 2006-12-20 2007-12-18 Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität ATE524446T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126689 2006-12-20
PCT/EP2007/064120 WO2008074795A1 (en) 2006-12-20 2007-12-18 Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity

Publications (1)

Publication Number Publication Date
ATE524446T1 true ATE524446T1 (de) 2011-09-15

Family

ID=39204903

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07857748T ATE524446T1 (de) 2006-12-20 2007-12-18 Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität

Country Status (6)

Country Link
US (3) US8722682B2 (de)
EP (1) EP2097389B1 (de)
JP (1) JP2010513390A (de)
AT (1) ATE524446T1 (de)
CA (1) CA2672957C (de)
WO (1) WO2008074795A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
US8901304B1 (en) 2013-11-05 2014-12-02 King Fahd University Of Petroleum And Minerals Benzo[D]imidazole derivatives of piperidine and piperazine
CN116554127A (zh) * 2022-01-28 2023-08-08 成都麻沸散医药科技有限公司 哌嗪取代苯酚类衍生物及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
DE19961334A1 (de) * 1999-12-17 2001-06-21 Roehm Gmbh Spritzgußverfahren für neutrale und säuregruppenhaltige (Meth)acrylat-Copolymere
MXPA03002370A (es) 2000-09-19 2003-10-15 Boehringer Ingelheim Pharma Nuevos derivados bencimidazolona n,n'-disustituidos con afinidad en los receptores de serotonina y dopamina.
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
DK1256343T3 (da) 2001-05-11 2006-10-30 Juergen K Dr Beck Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
US7115628B2 (en) 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
CA2450093C (en) 2001-08-02 2008-09-23 Bidachem S.P.A. Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
MEP55308A (en) 2002-05-22 2011-05-10 Boehringer Ingelheim Pharma New pharmaceutical compositions containing flibanserin polymorph a
US20040193452A1 (en) * 2003-01-06 2004-09-30 Laura Berman Method and system for computerized sexual function assessment of female users
US7041193B2 (en) 2003-05-14 2006-05-09 L & L Products, Inc. Method of adhering members and an assembly formed thereby
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
GB2413148A (en) 2004-04-16 2005-10-19 Per-Olof Eriksson Loft ladder assembly
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
KR200358845Y1 (ko) 2004-05-04 2004-08-12 김대연 구강내 환부에 삽입되는 광 섬유봉이 구비된 투시촬영장치
JP2008540673A (ja) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤誘発性性機能不全の治療方法
ES2646326T3 (es) * 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
EP1940357A2 (de) * 2005-09-30 2008-07-09 SmithKline Beecham Corporation Pharmazeutische zusammensetzungen
CA2626134C (en) * 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
DE102006010870A1 (de) 2006-03-07 2007-09-13 Henkel Kgaa Kosmetische Mittel mit Purin und/oder Purinderivaten I
DE602007004615D1 (de) * 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
AR062320A1 (es) * 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
EA200900270A1 (ru) 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
EP2126552A4 (de) 2007-02-16 2016-04-20 3M Innovative Properties Co Verfahren und vorrichtung für die beleuchtung von material zur automatischen inspektion
EP2129400A2 (de) 2007-03-28 2009-12-09 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzungen mit flibanserin und einem weiteren wirkstoff bei der behandlung von sexualerkrankungen
US8486452B2 (en) * 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts

Also Published As

Publication number Publication date
US20110015207A1 (en) 2011-01-20
CA2672957A1 (en) 2008-06-26
EP2097389A1 (de) 2009-09-09
JP2010513390A (ja) 2010-04-30
US8722682B2 (en) 2014-05-13
EP2097389B1 (de) 2011-09-14
WO2008074795A1 (en) 2008-06-26
US20150368204A1 (en) 2015-12-24
CA2672957C (en) 2015-04-14
US20150011564A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
ATE524446T1 (de) Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
MX338707B (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
NO20083630L (no) Nye pyridinderivater
MX2010005298A (es) Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
ATE483707T1 (de) 2-cyclopropylthiazolderivate
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
UA94639C2 (ru) Трициклические соединения и их применение как модуляторов глюкокортикоидного рецептора
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2011006843A (es) Dihidropiridona-amidas como moduladores de p2x7.
CR11866A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
BR112015013463A2 (pt) derivados de carboxamida indol como antagonistas do receptor de p2x7
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
CY1110276T1 (el) Αμινοαρυλο σουλφοναμιδικα παραγωγα ως λειτουργικοι συνδετες 5-ητ6
CR10371A (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la moduilacion del receptor de serotonina 5ht6
MX2009008286A (es) Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties